Skip to main content
MedPathMedPath Home
Clinical Trials/NCT00908349
NCT00908349
Completed
Phase 3

Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy

Supernus Pharmaceuticals, Inc.0 sites214 target enrollmentJune 2009
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPartial Epilepsy
InterventionsOxcarbazepine XR
DrugsOxcarbazepine XR

Overview

Phase
Phase 3
Intervention
Oxcarbazepine XR
Conditions
Partial Epilepsy
Sponsor
Supernus Pharmaceuticals, Inc.
Enrollment
214
Primary Endpoint
Percent Change in Seizure Rate
Status
Completed
Last Updated
8 years ago
OverviewInvestigatorsEligibility CriteriaArms & InterventionsOutcomesSimilar Trials

Overview

Brief Summary

Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)

Detailed Description

NAP

Registry
clinicaltrials.gov
Start Date
June 2009
End Date
November 2011
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

Oxcarbazepine XR

Open Label Study

Intervention: Oxcarbazepine XR

Outcomes

Primary Outcomes

Percent Change in Seizure Rate

Time Frame: one year

Measured as change from baseline to end of study

Similar Trials

Completed
Phase 4
Open Label Extension Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar I DisorderBipolar Disorder
NCT00139594Novartis181
Terminated
Phase 3
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic RetinopathyDiabetic Retinopathy
NCT00248157Novartis Pharmaceuticals105
Terminated
Phase 3
Extension Study of Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic RetinopathyDiabetic Retinopathy
NCT00248131Novartis Pharmaceuticals260
Terminated
Phase 3
Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor FluctuationsParkinson's Disease
NCT00505622Eisai Limited328
Completed
Phase 1
A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on PadsevonilEpilepsy
NCT03695094UCB Biopharma S.P.R.L.31